Fermenta Biotech Limited merges with its holding company, DIL Limited – synergies for accelerated growth

Fermenta Biotech Limited merges with its holding company, DIL Limited – synergies for accelerated growth

Free Press JournalUpdated: Tuesday, October 01, 2019, 07:07 PM IST
article-image
Representational Pic |

Mumbai : DIL Ltd. (BSE: DIL) announced the merger of its subsidiary, Fermenta Biotech Ltd. (FBL), one of the leading Vitamin D3 manufacturers globally, with DIL.

Pursuant to applications made by DIL and FBL to the National Company Law Tribunal, Mumbai (NCLT) for approval of the scheme of amalgamation of FBL with DIL, the NCLT has approved the said merger vide its Order dated 19th September, 2019.

The order of the NCLT has been uploaded on its website www.nclt.gov.in on 25th September, 2019.The intimation to BSE Limited regarding the Order has also been done subsequently on 25th September, 2019.

The copy of the said intimation is also available on www.dil.net. As per the approved scheme of amalgamation, post merger, the name of the combined entity will be ‘FERMENTA BIOTECH LIMITED’.

The merger took place purely in the interest of business growth, in order to combine resources of both companies, effectively manage operations, focus on business priorities and maximisation of stakeholders’ benefits.

The merger is also anticipated to bring greater efficiency in cash management and unfettered access to cash flows generated by the combined business.

Further, cost savings are expected to flow from more focused operational efforts, standardization of business processes and rationalization of administrative expenses.

Commenting on the development, Mr. Krishna Datla, Managing Director said, “The amalgamation represents a major milestone for us in carrying forward our legacy of over six decades. It is expected to combine the synergies of both companies that will enhance our operational efficiencies. Further, it will enable us to focus our resources to bring in value-added formats in the nutraceutical ingredients space in order to diversify our product portfolio.”

FBL caters to over 300 customers across 50 countries, with a worldwide distribution network across applications such as pharmaceuticals, food, dietary and nutritional supplements, feed, veterinary and rodenticides.

Apart from Vitamin D, FBL is a pioneer in the enzyme technologies space, offering enzymes for antibiotic synthesis and industrial applications. Moving forward, the combined entity shall augment its focus on the nutrition sector, by means of organic and inorganic growth opportunities.

About FBL:

Fermenta Biotech Limited (FBL), incorporated in 1986, is engaged in manufacturing of Vitamin D3, other specialty APIs, biological enzymes and offers integrated biotech based environmental solutions.

FBL has its head office and R&D centre located in Thane, along with two manufacturing facilities (cGMP certified) as follows:

- Kullu in Himachal Pradesh – setup in 1987, currently manufacturing Vitamin D3, specialty API’s and Enzymes;

- Dahej SEZ – set up in 2011 and currently manufacturing Vitamin D3.

For more information about the Company and its businesses, please visit the website https://www.fermentabiotech.com

For further details please contact:

Name: Mr. Prashant Nagre

Designation: Chief Executive Officer

Mob. No.: +91 98214 32513

Email id.: prashant.nagre@fermentabiotech.com

RECENT STORIES

Finolex Industries Enhance Premature Infants Care At Symbiosis Hospital In Memory Of Founders

Finolex Industries Enhance Premature Infants Care At Symbiosis Hospital In Memory Of Founders

Confluence Of Ideas, Actions And Play-Based Learning Explored At Reliance Foundation’s Landmark...

Confluence Of Ideas, Actions And Play-Based Learning Explored At Reliance Foundation’s Landmark...

Muthoot Finance Broadened Its 6400+ Branch Network By Inaugurating Its First Delhi Metro Rail...

Muthoot Finance Broadened Its 6400+ Branch Network By Inaugurating Its First Delhi Metro Rail...

IAA & ISA To Host Retrospect And Prospects In Mumbai

IAA & ISA To Host Retrospect And Prospects In Mumbai

ZEE's MD & CEO Inaugurates State-Of-The-Art Kidney Centre At Breach Candy Hospital

ZEE's MD & CEO Inaugurates State-Of-The-Art Kidney Centre At Breach Candy Hospital